Lupin gets UK NICE recommendation for Namuscla in NDM
Lupin said that the UK’ National Institute for Health and Care Excellence (NICE) has recommended Namuscla (mexiletine), an antimyotonic agent, for the approval of its use in the treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM). The Indian pharma company, through its subsidiary — Lupin Healthcare (UK), has agreed to a confidential […]